Severe Pleuropericarditis and Cardiomyopathy Induced by High Dose Interferon alpha-2b

Ohad Benjamini MD1, Oded Kimhi MD1,2 and Michael Lishner MD1,2

1Department of Medicine A, Meir Medical Center, Kfar Saba, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

Key words: interferon, cardiomyopathy, pleuropericarditis

High dose interferon alpha-2b is used as adjuvant therapy for cutaneous melanoma and has been shown to have a reproducible benefit [1]. The drug has many side effects, of which constitutional flu-like symptoms are the most prevalent. A multitude of other adverse effects have been described involving every major organ system. Cardiotoxicity is rare and previous reports have described various arrhythmias, cardiomyopathy and ischemic heart disease.

We report a case of severe cardiotoxicity during treatment of melanoma with high dose IFNα-2b. This potentially lethal effect reversed upon cessation of interferon and steroid administration.

Patient Description

A 63 year old man was admitted to the department of internal medicine because of dyspnea, weakness and left pleuritic chest pain that appeared 2 days prior to admission. According to his history, 22 years previously he had undergone splenectomy and removal of a tumor mass involving the stomach, which was diagnosed as diffuse large B cell non-Hodgkin’s lymphoma. A full course of chemotherapy consisting of cyclophosphamide, Adriamycin, vincristine and dexamethasone (CHOP) was administered. The total cumulative dose of Adriamycin was 400 mg/m². Radiotherapy was not administered. He had been in remission ever since. He had no cardiac history other than an insertion of a permanent pacemaker due to symptomatic fascicular block of unknown etiology 6 months before the current presentation. A recent echocardiography revealed normal systolic function. He had been asymptomatic since the pacemaker insertion.

A malignant melanoma involving the left inguinal lymph nodes was diagnosed 3 months before presentation. The primary site was not identified in spite of careful investigation. After excision of the inguinal nodes, he received high dose IFNα-2b (18 x 10⁶ units per day intravenously) for 1 month. No other medications were administered. The interferon treatment was suspended a week before his admission due to elevated liver enzymes. Radiotherapy directed to the left inguinal area alone was started 2 weeks prior to the current admission.

On physical examination he was afebrile but looked sick and was tachypneic and hypotensive (85/55 mmHg). Breathing sounds were diminished bilaterally and percussion was dull. A third heart sound was heard over the precordium as well as a pericardial friction rub. The most commonly reported adverse effects are transient hypotension upon initiation of treatment, atrial and ventricular arrhythmias, congestive heart failure, leukopenia and neutropenia. Our patient is unique since he presented with congestive heart failure (S₃ and global left ventricular dysfunction) and pleural effusion (pericardial friction rub and exudative pleural effusion).

Cardiac toxicity due to interferon is uncommon and the literature survey yielded only small case series and case reports. The most commonly reported adverse effects are transient hypotension upon initiating treatment, atrial and ventricular arrhythmias, congestive heart failure, leukopenia and neutropenia. Our patient is unique since he presented with both congestive heart failure (S₃ and global left ventricular dysfunction) and inflamation (pericardial friction rub and exudative cellular pleural effusion).

Comment

There are no established predisposing factors for interferon cardiotoxicity. Patients with previous heart disease are probably at higher risk for arrhythmia and ischemic manifestations [3], but not for cardiomyopathy. IFNα is the most cardiotoxic of the three interferons, followed by IFNγ and IFNβ. Toxicity does not depend on the daily dose, the total amount, or the duration of treatment.

It is plausible, but not established, that...
radiotherapy and other cardiotoxic agents predispose patients to higher rates of interferon cardiotoxicity. It is possible that our patient had subclinical doxorubicin-induced cardiac disease which exposed him to the adverse effects of interferon. However, since the cardiotoxicity was reversible, and the fact that the total dose of doxorubicin was below the cardiac toxic range, and that it was administered 20 years earlier suggest that interferon was the major cause of the cardiac damage.

The mechanism of interferon cardiotoxicity is unclear and is probably multifactorial. Experimental infusion of recombinant IFNα may cause arrhythmia and ischemia. There is evidence that interferon may damage endothelial cells, cause the thickening of capillary walls, and induce deposition of immune complexes. Interferon evokes the release of several cytokines, including tumor necrosis factor alpha, and interleukins 2, 6 and 1, affecting autonomic sympathetic nerve activity and vasopressor responses [4]. Interferon has been associated with exacerbation or induction of a wide variety of clinical and serological immune disorders, including systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, thyroid disease and diabetes mellitus. There is only a single report of autoimmune pericarditis that was not accompanied by congestive heart failure.

Treatment of interferon-induced cardiotoxicity rests mainly on early recognition and drug discontinuation. There is a high degree of individual variation in toxicity, but most adverse events are reversible upon cessation of the drug. Arrhythmia, ischemia and congestive heart failure are treated with standard measures. Since the cardiac symptoms occurred 1 week after discontinuation of the drug and were associated with an inflammatory response, we decided to add steroids to the treatment. Indeed, within several days a dramatic improvement, both subjective and objective, was noted. For causality assessment, we used the Naranjo ADR Probability Scale, a validated tool used to determine the likelihood that the adverse drug reaction is caused by the implicated medication. The Naranjo algorithm requires a series of questions to be answered and scored. The total calculated score indicates the likelihood – from doubtful, possible, and probable to highly probable – of causing an adverse drug reaction. The appearance of cardiomyopathy and pleuropericarditis after the administration of high dose interferon, and the prompt improvement in the patient’s condition after the drug was discontinued without an alternative explanation for this adverse event, yielded a total score of +5 (range -4 to +13) on the Naranjo ADR Probability Scale and indicate a probable relationship [5].

In summary, we report a patient with no significant history of myocardial dysfunction who developed a clinical and echocardiographic picture of cardiomyopathy and pleuropericarditis after treatment with high dose interferon. It highlights previously unreported inflammatory-type adverse cardiac effects of high dose interferon, which are reversible and responsive to steroid treatment.

References

Correspondence: Dr M. Lishner, Dept. of Medicine A, Meir Medical Center, Kfar Saba 44281, Israel.
Phone: (972-9) 747-2516
Fax: (972-9) 746-781
email: michael2@clalit.org.il

Capsule

Function of thymic Lti cells

During their passage through the thymus, developing T cells are selected on the basis of their capacity to recognize foreign antigens while remaining tolerant of the body’s own constituents. This is achieved in part through interacting (in the thymic medulla) with specialized epithelial cells that offer up small samples of self proteins whose expression is largely restricted to other tissues. This supplemental expression of the self proteins is regulated by the transcription factor Aire and contributes to preventing autoimmunity. Rossi et al. used organ cultures derived from fetal mouse thymus to ascertain that hematopoietic cells already known to induce peripheral lymphoid tissue, and aptly named lymphoid tissue-inducing (LTI) cells, also regulate the development of a subset of medullary epithelial cells and their expression of Aire. This depended on the receptor activator nuclear factor-KB ligand (RANKL), and autoimmunity-like symptoms ensued after the transplantation of RANK-deficient thymus into athymic mice. Previous studies have reported that another tumor necrosis factor family member (lymphotoxin-alpha) is expressed in LTI cells and has similar effects, so resolving the contributions of each in regulating immunological tolerance will be of interest.

J Exp Med 2007;204:10.1084
Eitan Israeli